Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

周一，摩根大通对纳斯达克上市的Vertex Pharmaceuticals Incorporated（股票代码：VRTX）的目标价做出了微调，从503.00美元下调至500.00美元。该公司维持了对该股票的增持评级。根据 InvestingPro 数据，该股票目前交易价格为397.27美元，过去一周下跌了15%。此次调整是在Alyf trek获得提前批准并符合市场预期后做出的。

12月19日，专注于罕见病治疗的药品开发公司Vertex ...

周一，Truist Securities调整了市值1,010亿美元的知名生物技术公司Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的目标价。该股票在过去一周下跌超过15%，承受了巨大压力。该公司分析师将目标价从之前的550美元下调至460美元，同时维持对该股票的买入评级。根据 InvestingPro ...

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

摩根大通：将Vertex Pharmaceuticals的目标价从503美元下调至500美元，但维持“增持”评级。(格隆汇) ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately. Vertex Pharmaceuticals' suzetrigine is an investigational pain ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.